XOMA Royalty Corporation (NASDAQ:XOMA) Given Consensus Recommendation of “Hold” by Analysts

XOMA Royalty Corporation (NASDAQ:XOMA) has been given an average recommendation of “Hold” by the five research firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have given a buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $60.60.

A number of equities research analysts have weighed in on XOMA shares. Zacks Research downgraded shares of XOMA Royalty from a “hold” rating to a “strong sell” rating in a research note on Tuesday, November 18th. UBS Group set a $76.00 target price on shares of XOMA Royalty in a research report on Tuesday, December 9th. HC Wainwright lowered their target price on shares of XOMA Royalty from $104.00 to $97.00 and set a “buy” rating on the stock in a research note on Thursday, December 11th. Stifel Nicolaus set a $50.00 price target on shares of XOMA Royalty in a research note on Friday, December 12th. Finally, Benchmark reaffirmed a “buy” rating on shares of XOMA Royalty in a report on Friday, December 12th.

XOMA Royalty Trading Down 0.2%

Shares of XOMA opened at $29.85 on Monday. The stock’s 50-day moving average price is $29.67 and its 200 day moving average price is $31.25. The company has a quick ratio of 3.91, a current ratio of 3.91 and a debt-to-equity ratio of 1.07. The firm has a market capitalization of $369.54 million, a price-to-earnings ratio of 40.34 and a beta of 0.89. XOMA Royalty has a 12-month low of $18.35 and a 12-month high of $39.92.

XOMA Royalty (NASDAQ:XOMA) last announced its quarterly earnings data on Wednesday, November 12th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.33). The firm had revenue of $9.35 million for the quarter, compared to analyst estimates of $11.47 million. XOMA Royalty had a return on equity of 2.91% and a net margin of 32.28%. As a group, research analysts predict that XOMA Royalty will post -1.41 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Owen Hughes purchased 100,000 shares of the stock in a transaction on Thursday, December 4th. The shares were purchased at an average cost of $25.05 per share, for a total transaction of $2,505,000.00. Following the completion of the transaction, the chief executive officer directly owned 102,000 shares of the company’s stock, valued at approximately $2,555,100. The trade was a 5,000.00% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 7.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On XOMA Royalty

Several institutional investors and hedge funds have recently made changes to their positions in the company. Russell Investments Group Ltd. increased its position in shares of XOMA Royalty by 3,436.4% during the 3rd quarter. Russell Investments Group Ltd. now owns 778 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 756 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in XOMA Royalty by 203.1% during the second quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company’s stock worth $57,000 after buying an additional 1,523 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of XOMA Royalty by 13.9% during the second quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock worth $112,000 after buying an additional 543 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of XOMA Royalty in the second quarter valued at approximately $116,000. Finally, BNP Paribas Financial Markets raised its stake in shares of XOMA Royalty by 266.6% in the third quarter. BNP Paribas Financial Markets now owns 3,226 shares of the biotechnology company’s stock valued at $124,000 after acquiring an additional 2,346 shares during the last quarter. Institutional investors and hedge funds own 95.92% of the company’s stock.

About XOMA Royalty

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.